ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»ppharm-1504Research ArticleИНФОРМАЦИЯ СОЮЗА ПЕДИАТРОВ РОССИИFROM THE UNION OF PEDIATRICIANS OF RUSSIAПрофилактика тяжелых инфекций у пациентов с генетическими нарушениями регуляции системы комплемента, получающих терапию экулизумабом: пресс-релиз о проведении Междисциплинарного совета экспертовPREVENTION OF SEVERE INFECTIONS IN PATIENTS WITH GENETIC DISORDERS OF THE COMPLEMENT SYSTEM REGULATION TREATING WITH ECULIZUMAB: PRESS RELEASE ON THE INTERDISCIPLINARY EXPERT COUNCIL MEETINGстатьяРедакционнаяArticleEditorial2017030520171416672Copyright © статья Р., 20172017статья Р.article E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/1504
.
.
ReferencesNoris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844–1859. doi: 10.2215/CJN.02210310.Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844–1859. doi: 10.2215/CJN.02210310.Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267–1279. doi: 10.1182/blood-2005-10-007252.Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267–1279. doi: 10.1182/blood-2005-10-007252.Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18(8):2392–2400. doi: 10.1681/ASN.2006080811.Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18(8):2392–2400. doi: 10.1681/ASN.2006080811.Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol. 2011;3:5–12. doi: 10.2147/CPAA.S17904.Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol. 2011;3:5–12. doi: 10.2147/CPAA.S17904.Ardissino G, Tel F, Testa S, et al. Skin involvement in atypical hemolytic uremic syndrome. Am J Kidney Dis. 2014;63(4):652–655. doi: 10.1053/j.ajkd.2013.09.020.Ardissino G, Tel F, Testa S, et al. Skin involvement in atypical hemolytic uremic syndrome. Am J Kidney Dis. 2014;63(4):652–655. doi: 10.1053/j.ajkd.2013.09.020.Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19): 1253–1258. doi: 10.1056/NEJM199511093331904.Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19): 1253–1258. doi: 10.1056/NEJM199511093331904.Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348(9027):573–577. doi: 10.1016/S0140-6736(95)12360-1.Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348(9027):573–577. doi: 10.1016/S0140-6736(95)12360-1.Kelly R, Richards S, Hillmen P, Hill A. The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Ther Clin Risk Manag. 2009;5:911–921. doi: 10.2147/TCRM.S3334.Kelly R, Richards S, Hillmen P, Hill A. The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Ther Clin Risk Manag. 2009;5:911–921. doi: 10.2147/TCRM.S3334.McKeage K. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011;71(17):2327–2345. doi: 10.2165/11208300-000000000-00000.McKeage K. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011;71(17):2327–2345. doi: 10.2165/11208300-000000000-00000.Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12): 4123–4128. doi: 10.1182/blood-2007-06-095646.Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12): 4123–4128. doi: 10.1182/blood-2007-06-095646.Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137(3):181– 192. doi: 10.1111/j.1365-2141.2007.06554.x.Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137(3):181– 192. doi: 10.1111/j.1365-2141.2007.06554.x.Lee J, Jun Ho J, Sung Soo Y, et al. High prevalence and mortality associated with thromboembolism in Asian patients with paroxysmal noctu rnal hemоglobinuria (PNH). In: Haematologica. Supplement 2. 15th Congress of The European Hematology Association, Spain, Barcelona, June 10–13, 2010. Pavia: Societa italiana di ematologia; 2010. p. 205–206.Lee J, Jun Ho J, Sung Soo Y, et al. High prevalence and mortality associated with thromboembolism in Asian patients with paroxysmal noctu rnal hemоglobinuria (PNH). In: Haematologica. Supplement 2. 15th Congress of The European Hematology Association, Spain, Barcelona, June 10–13, 2010. Pavia: Societa italiana di ematologia; 2010. p. 205–206.CDC. Updated recommendations for use of meningococcal conjugate vaccines — Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2011;60:72–6.CDC. Updated recommendations for use of meningococcal conjugate vaccines — Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2011;60:72–6.www.gov.uk [Internet]. Public Health England. Immunisation of individuals with underlying medical conditions: the green book, chapter 7 [updated 2016 Sep 29; cited 2017 Jan 15]. Available from: https://www.gov.uk/government/publications/immunisation-of- individualswith-underlying-medical-conditions-the-green-book-chapter-7.www.gov.uk [Internet]. Public Health England. Immunisation of individuals with underlying medical conditions: the green book, chapter 7 [updated 2016 Sep 29; cited 2017 Jan 15]. Available from: https://www.gov.uk/government/publications/immunisation-of- individualswith-underlying-medical-conditions-the-green-book-chapter-7.Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86(47):521–540.Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86(47):521–540.www.who.int [интернет]. Документ по позиции ВОЗ в отношении вакцинации против гемофильной инфекции типа b (Hib) — июль 2013 года. [WHO position paper on H. influenzae type b (Hib) Vaccination — July 2013] [доступ от 21.01.2017]. Доступ по ссылке http://www.who.int/immunization/Hib_Rus.pdfwww.who.int [интернет]. Документ по позиции ВОЗ в отношении вакцинации против гемофильной инфекции типа b (Hib) — июль 2013 года. [WHO position paper on H. influenzae type b (Hib) Vaccination — July 2013] [доступ от 21.01.2017]. Доступ по ссылке http://www.who.int/immunization/Hib_Rus.pdf
The authors declare that there are no conflicts of interest present.